Skip To Main Content
Lars Bardtrum on Muck Rack

Lars Bardtrum

As seen in: Color Research & Application, Wiley Online Library, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lars

Contact Lars, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

|
By Jens Aberle, Lars Bardtrum, Erik Christiansen, Sue D Pedersen
| The Lancet Verified
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Open in Who Shared View Duplicates (691) Issue with article?

Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis

|
By Juris J Meier, Lars Bardtrum, Brian Malling
| Wiley Online Library Verified
RESEARCH LETTER This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.14957.
Open in Who Shared Issue with article?

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice - Sesti - - Diabet

|
By Giorgio Sesti, Lars Bardtrum, Selcuk Dagdelen
| Color Research & Application Verified
1 INTRODUCTION Because of its progressive nature, people with type 2 diabetes (T2D) often eventually require injectable therapies to achieve glycaemic control.
Open in Who Shared Issue with article?
See all 5 articles